333 related articles for article (PubMed ID: 31546754)
21. Serum profiling identifies novel muscle miRNA and cardiomyopathy-related miRNA biomarkers in Golden Retriever muscular dystrophy dogs and Duchenne muscular dystrophy patients.
Jeanson-Leh L; Lameth J; Krimi S; Buisset J; Amor F; Le Guiner C; Barthélémy I; Servais L; Blot S; Voit T; Israeli D
Am J Pathol; 2014 Nov; 184(11):2885-98. PubMed ID: 25194663
[TBL] [Abstract][Full Text] [Related]
22. Flow Cytometry-Defined CD49d Expression in Circulating T-Lymphocytes Is a Biomarker for Disease Progression in Duchenne Muscular Dystrophy.
Savino W; Pinto-Mariz F; Mouly V
Methods Mol Biol; 2018; 1687():219-227. PubMed ID: 29067667
[TBL] [Abstract][Full Text] [Related]
23. Moving towards successful exon-skipping therapy for Duchenne muscular dystrophy.
Nakamura A
J Hum Genet; 2017 Oct; 62(10):871-876. PubMed ID: 28566768
[TBL] [Abstract][Full Text] [Related]
24. MicroRNAs in Dystrophinopathy.
Lee A; Moon J; Yu J; Kho C
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887128
[TBL] [Abstract][Full Text] [Related]
25. Duchenne Muscular Dystrophy: From Diagnosis to Therapy.
Falzarano MS; Scotton C; Passarelli C; Ferlini A
Molecules; 2015 Oct; 20(10):18168-84. PubMed ID: 26457695
[TBL] [Abstract][Full Text] [Related]
26. Molecular diagnosis of Duchenne/Becker muscular dystrophy: enhanced detection of dystrophin gene rearrangements by oligonucleotide array-comparative genomic hybridization.
del Gaudio D; Yang Y; Boggs BA; Schmitt ES; Lee JA; Sahoo T; Pham HT; Wiszniewska J; Chinault AC; Beaudet AL; Eng CM
Hum Mutat; 2008 Sep; 29(9):1100-7. PubMed ID: 18752307
[TBL] [Abstract][Full Text] [Related]
27. Duchenne and Becker Muscular Dystrophies: A Review of Animal Models, Clinical End Points, and Biomarker Quantification.
Wilson K; Faelan C; Patterson-Kane JC; Rudmann DG; Moore SA; Frank D; Charleston J; Tinsley J; Young GD; Milici AJ
Toxicol Pathol; 2017 Oct; 45(7):961-976. PubMed ID: 28974147
[TBL] [Abstract][Full Text] [Related]
28. Rescue of dystrophin mRNA of Duchenne muscular dystrophy by inducing exon skipping.
Matsuo M; Takeshima Y
Acta Myol; 2005 Oct; 24(2):110-4. PubMed ID: 16550927
[TBL] [Abstract][Full Text] [Related]
29. Therapeutic Applications of CRISPR/Cas for Duchenne Muscular Dystrophy.
Wong TWY; Cohn RD
Curr Gene Ther; 2017; 17(4):301-308. PubMed ID: 29173172
[TBL] [Abstract][Full Text] [Related]
30. Dystrophin-deficient large animal models: translational research and exon skipping.
Yu X; Bao B; Echigoya Y; Yokota T
Am J Transl Res; 2015; 7(8):1314-31. PubMed ID: 26396664
[TBL] [Abstract][Full Text] [Related]
31. A novel canine model for Duchenne muscular dystrophy (DMD): single nucleotide deletion in DMD gene exon 20.
Mata López S; Hammond JJ; Rigsby MB; Balog-Alvarez CJ; Kornegay JN; Nghiem PP
Skelet Muscle; 2018 May; 8(1):16. PubMed ID: 29843823
[TBL] [Abstract][Full Text] [Related]
32. [Genetic analysis and prenatal diagnosis of Duchenne or Becker muscular dystrophy].
Zhao W; Jiang N; Li S; Li JS; Miao Y; Liang SY; Yu DY
Zhonghua Fu Chan Ke Za Zhi; 2019 Apr; 54(4):226-231. PubMed ID: 31006187
[No Abstract] [Full Text] [Related]
33. Exon Skipping Therapy Using Phosphorodiamidate Morpholino Oligomers in the mdx52 Mouse Model of Duchenne Muscular Dystrophy.
Miyatake S; Mizobe Y; Takizawa H; Hara Y; Yokota T; Takeda S; Aoki Y
Methods Mol Biol; 2018; 1687():123-141. PubMed ID: 29067660
[TBL] [Abstract][Full Text] [Related]
34. Use of capillary Western immunoassay (Wes) for quantification of dystrophin levels in skeletal muscle of healthy controls and individuals with Becker and Duchenne muscular dystrophy.
Beekman C; Janson AA; Baghat A; van Deutekom JC; Datson NA
PLoS One; 2018; 13(4):e0195850. PubMed ID: 29641567
[TBL] [Abstract][Full Text] [Related]
35. Next Generation Sequencing approach to molecular diagnosis of Duchenne muscular dystrophy; identification of a novel mutation.
Ebrahimzadeh-Vesal R; Teymoori A; Azimi-Nezhad M; Hosseini FS
Gene; 2018 Feb; 644():1-3. PubMed ID: 29246534
[TBL] [Abstract][Full Text] [Related]
36. In Vivo Evaluation of Multiple Exon Skipping with Peptide-PMOs in Cardiac and Skeletal Muscles in Dystrophic Dogs.
Maruyama R; Aoki Y; Takeda S; Yokota T
Methods Mol Biol; 2018; 1828():365-379. PubMed ID: 30171554
[TBL] [Abstract][Full Text] [Related]
37. Cardiac Involvement in Duchenne Muscular Dystrophy and Related Dystrophinopathies.
Mavrogeni SI; Markousis-Mavrogenis G; Papavasiliou A; Papadopoulos G; Kolovou G
Methods Mol Biol; 2018; 1687():31-42. PubMed ID: 29067654
[TBL] [Abstract][Full Text] [Related]
38. Non-Invasive Biomarkers for Duchenne Muscular Dystrophy and Carrier Detection.
Anaya-Segura MA; García-Martínez FA; Montes-Almanza LA; Díaz BG; Avila-Ramírez G; Alvarez-Maya I; Coral-Vazquez RM; Mondragón-Terán P; Escobar-Cedillo RE; García-Calderón N; Vazquez-Cardenas NA; García S; López-Hernandez LB
Molecules; 2015 Jun; 20(6):11154-72. PubMed ID: 26091074
[TBL] [Abstract][Full Text] [Related]
39. Contributions of Japanese patients to development of antisense therapy for DMD.
Matsuo M; Takeshima Y; Nishio H
Brain Dev; 2016 Jan; 38(1):4-9. PubMed ID: 26094594
[TBL] [Abstract][Full Text] [Related]
40. New developments in the use of gene therapy to treat Duchenne muscular dystrophy.
Jarmin S; Kymalainen H; Popplewell L; Dickson G
Expert Opin Biol Ther; 2014 Feb; 14(2):209-30. PubMed ID: 24308293
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
